Vaccinex, Inc. (VCNX)
USD 1.0
(66.67%)
USD 1.0
(66.67%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.94 Million USD | 113.43% |
| 2022 | 2.78 Million USD | 14.52% |
| 2021 | 2.43 Million USD | -83.02% |
| 2020 | 14.31 Million USD | 108.11% |
| 2019 | 6.87 Million USD | 2.87% |
| 2018 | 6.68 Million USD | -9.0% |
| 2017 | 7.34 Million USD | 19.06% |
| 2016 | 6.17 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 5.23 Million USD | 11.01% |
| 2024 Q1 | 4.71 Million USD | -20.7% |
| 2023 Q2 | 3.5 Million USD | 40.6% |
| 2023 Q1 | 2.49 Million USD | -10.38% |
| 2023 FY | 5.94 Million USD | 113.43% |
| 2023 Q4 | 5.94 Million USD | -7.55% |
| 2023 Q3 | 6.42 Million USD | 83.21% |
| 2022 Q4 | 2.78 Million USD | 21.36% |
| 2022 Q3 | 2.29 Million USD | 40.82% |
| 2022 Q1 | 1.93 Million USD | -20.49% |
| 2022 FY | 2.78 Million USD | 14.52% |
| 2022 Q2 | 1.62 Million USD | -15.73% |
| 2021 Q3 | 3.29 Million USD | -51.83% |
| 2021 Q4 | 2.43 Million USD | -26.31% |
| 2021 Q1 | 7.9 Million USD | -44.79% |
| 2021 FY | 2.43 Million USD | -83.02% |
| 2021 Q2 | 6.84 Million USD | -13.34% |
| 2020 Q2 | 8.67 Million USD | 31.07% |
| 2020 Q4 | 14.31 Million USD | -4.32% |
| 2020 FY | 14.31 Million USD | 108.11% |
| 2020 Q1 | 6.62 Million USD | -3.75% |
| 2020 Q3 | 14.96 Million USD | 72.42% |
| 2019 Q4 | 6.87 Million USD | -0.26% |
| 2019 Q2 | 9.5 Million USD | 36.53% |
| 2019 Q1 | 6.95 Million USD | 4.08% |
| 2019 FY | 6.87 Million USD | 2.87% |
| 2019 Q3 | 6.89 Million USD | -27.42% |
| 2018 Q1 | 6.54 Million USD | -10.93% |
| 2018 FY | 6.68 Million USD | -9.0% |
| 2018 Q4 | 6.68 Million USD | 8.96% |
| 2018 Q3 | 6.13 Million USD | -30.78% |
| 2018 Q2 | 8.86 Million USD | 35.45% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | 7.34 Million USD | 0.0% |
| 2017 FY | 7.34 Million USD | 19.06% |
| 2016 FY | 6.17 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -23.151% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -150.084% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 84.736% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 95.52% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -113.818% |
| Better Therapeutics, Inc. | 23.84 Million USD | 75.078% |
| Calithera Biosciences, Inc. | 8.28 Million USD | 28.271% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | 40.426% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 77.44% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 81.304% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 91.442% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | 25.216% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 87.649% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 96.223% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -69.483% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 72.09% |
| Molecular Templates, Inc. | 31.17 Million USD | 80.937% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 52.521% |
| NexImmune, Inc. | 5.08 Million USD | -16.871% |
| Orgenesis Inc. | 35.53 Million USD | 83.278% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 64.014% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -2130.363% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -158.873% |
| Scopus BioPharma Inc. | 7.45 Million USD | 20.289% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 98.798% |
| Statera Biopharma, Inc. | 22.67 Million USD | 73.797% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | 45.556% |
| Trevena, Inc. | 48.26 Million USD | 87.688% |
| Vaxxinity, Inc. | 30.94 Million USD | 80.798% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -201.879% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 84.515% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -115.168% |